Claims for Patent: 9,161,988

Summary for Patent: 9,161,988

Title:	Multimeric peptide conjugates and uses thereof
Abstract:	The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.
Inventor(s):	Castaigne; Jean-Paul (Mont-Royal, CA), Demeule; Michel (Beaconsfield, CA), Che; Christian (Longueuil, CA), Thiot; Carine (Montreal, CA), Gagnon; Catherine (Montreal-Nord, CA), Lawrence; Betty (Bolton, CA)
Assignee:	Angiochem Inc. (Montreal, CA)
Application Number:	13/382,069
Patent Claims:	1. A compound having a structure comprising the formula: A.sup.1-X.sup.1-A.sup.2 wherein A.sup.1 is a peptide vector comprising the amino acid sequence of SEQ ID NO:114; A.sup.2 is a peptide vector comprising the amino acid sequence of SEQ ID NO:97; and X.sup.1 is a linker comprising a carbon-sulfur bond formed by reaction of a maleimido group of the linker and the sulfhydryl group of the Cys at position 20 of SEQ ID NO:114 of A.sup.1. 2. The compound of claim 1, having a structure comprising the formula: ##STR00046## wherein B.sup.1 is an agent; and Y.sup.1 is a linker joining A.sup.1 to B.sup.1. 3. The compound of claim 1, wherein X.sup.1 is a maleimido propionic acid linker. 4. The compound of claim 2, wherein Y.sup.1 is a maleimido hexanoic acid linker. 5. The compound of claim 4, wherein said compound has the structure: ##STR00047## 6. The compound of claim 2, wherein said agent is a therapeutic agent. 7. The compound of claim 6, wherein said therapeutic agent is selected from the group consisting of an anticancer agent, a therapeutic nucleic acid, a GLP-1 agonist, leptin, neurotensin, glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and an antibody. 8. The compound of claim 7, wherein said anticancer agent is selected from the group consisting of paclitaxel, vinblastine, vincristine, etoposide, doxorubicin, cyclophosphamide, docetaxel, melphalan, chlorambucil, abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anakinra, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan, calusterone, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, cisplatin, cladribine, clofarabine, cytarabine, dacarbazine, dactinomycin, actinomycin D, dalteparin, darbepoetin alfa, dasatinib, daunorubicin, daunomycin, decitabine, denileukin, denileukin diftitox, dexrazoxane, dromostanolone propionate, eculizumab, epirubicin, epoetin alfa, erlotinib, estramustine, exemestane, fentany, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin, histrelin, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, Interferon alfa-2b, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide, levamisole, Iomustine, meclorethamine, megestrol, mercaptopurine, mesna, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oprelvekin, oxaliplatin, palifermin, pamidronate, panitumumab, pegademase, pegaspargase, pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentostatin, pipobroman, plicamycin, porfimer, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, sorafenib, streptozocin, sunitinib, talc, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, Tositumomab/I-131, trastuzumab, tretinoin, uracil mustard, valrubicin, vinorelbine, vorinostat, zoledronate, zoledronic acid and a pharmaceutically acceptable salt thereof. 9. The compound of claim 7, wherein said therapeutic nucleic acid is an RNAi agent capable of silencing EGFR or VEGF expression. 10. The compound of claim 7, where said therapeutic agent is a GLP-1 agonist, exendin-4 or a fragment thereof having GLP-1 agonist activity, [Lys.sup.39]exendin-4, or [Cys.sup.32] exendin-4. 11. The compound of claim 7, wherein said therapeutic agent is leptin, full-length human leptin, mature human leptin, or leptin.sub.116-130. 12. The compound of claim 7, wherein said therapeutic agent is neurotensin, human neurotensin, human neurotensin(8-13), or pELYENKPRRPYIL-OH, where pE represents L-pyroglutamic acid. 13. The compound of claim 7, wherein said therapeutic agent is GDNF BDNF, a full length GDNF, a full length BDNF, a mature form of GDNF, a mature form of BDNF, or human GDNF.sup.78-211. 14. The compound of claim 7, wherein said antibody is a monoclonal antibody, a monoclonal antibody that specifically binds to the amyloid-.beta. protein or to a fragment thereof, or is selected from the group consisting of bapineuzumab and solanezumab.

Details for Patent 9,161,988

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2029-07-02
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2029-07-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-07-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-07-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-07-02
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	06/01/1989		2029-07-02
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234			2029-07-02